within Pharmacolibrary.Drugs.ATC.L;

model L01CB01
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.7500000000000002e-05,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0076,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0035,
    k12             = 4.8,
    k21             = 4.8
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01CB01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Etoposide is a topoisomerase II inhibitor used as an antineoplastic agent for the treatment of various malignancies including small-cell lung cancer, testicular cancer, lymphoma, and leukemia. It is commonly administered intravenously or orally and is still approved and widely used in cancer chemotherapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in adult cancer patients following intravenous administration; large multicenter population PK study.</p><h4>References</h4><ol><li><p>Kato, Y, et al., &amp; Ueda, K (2003). Pharmacokinetics of etoposide with intravenous drug administration in children and adolescents. <i>Pediatrics international : official journal of the Japan Pediatric Society</i> 45(1) 74–79. DOI:<a href=&quot;https://doi.org/10.1046/j.1442-200x.2003.01675.x&quot;>10.1046/j.1442-200x.2003.01675.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12654074/&quot;>https://pubmed.ncbi.nlm.nih.gov/12654074</a></p></li><li><p>Fleming, RA, et al., &amp; Stewart, CF (1989). Etoposide: an update. <i>Clinical pharmacy</i> 8(4) 274–293. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2653712/&quot;>https://pubmed.ncbi.nlm.nih.gov/2653712</a></p></li><li><p>Reif, S, et al., &amp; Jaehde, U (2002). Population pharmacokinetics of etoposide. <i>International journal of clinical pharmacology and therapeutics</i> 40(12) 578–579. DOI:<a href=&quot;https://doi.org/10.5414/cpp40578&quot;>10.5414/cpp40578</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12503821/&quot;>https://pubmed.ncbi.nlm.nih.gov/12503821</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01CB01;
